NASDAQ:AXNX Axonics - AXNX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $54.41 -1.60 (-2.86%) (As of 03/30/2023 05:11 PM ET) Add Compare Share Share Today's Range$54.01▼$57.0150-Day Range$52.60▼$62.6652-Week Range$38.41▼$79.92Volume739,110 shsAverage Volume694,362 shsMarket Capitalization$2.72 billionP/E RatioN/ADividend YieldN/APrice Target$79.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Axonics MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside45.2% Upside$79.00 Price TargetShort InterestBearish7.67% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.43Based on 7 Articles This WeekInsider TradingSelling Shares$11.94 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.58) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector315th out of 1,009 stocksSurgical & Medical Instruments Industry28th out of 103 stocks 3.4 Analyst's Opinion Consensus RatingAxonics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.00, Axonics has a forecasted upside of 45.2% from its current price of $54.41.Amount of Analyst CoverageAxonics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.67% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Axonics has recently decreased by 2.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxonics does not currently pay a dividend.Dividend GrowthAxonics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Incontinence medication", "Implants and prostheses", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Axonics is -1.38. Previous Next 2.5 News and Social Media Coverage News SentimentAxonics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Axonics this week, compared to 3 articles on an average week.Search Interest1 people have searched for AXNX on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axonics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,942,021.00 in company stock.Percentage Held by InsidersOnly 2.31% of the stock of Axonics is held by insiders.Percentage Held by Institutions97.49% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axonics are expected to grow in the coming year, from ($0.58) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics is -41.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics is -41.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics has a P/B Ratio of 4.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axonics (NASDAQ:AXNX) StockAxonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.Read More Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXNX Stock News HeadlinesMarch 28, 2023 | americanbankingnews.comAnalyzing Universal Media Group (OTCMKTS:UMGP) & Axonics (NASDAQ:AXNX)March 25, 2023 | americanbankingnews.comAxonics (NASDAQ:AXNX) Stock Rating Upgraded by Needham & Company LLCMarch 30, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 7, 2023 | finance.yahoo.comAxonics to Participate in the SUFU 2023 Winter MeetingMarch 1, 2023 | finance.yahoo.comAxonics Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsMarch 1, 2023 | finance.yahoo.comAxonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue EstimatesFebruary 22, 2023 | finance.yahoo.comAxonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 8, 2023 | finance.yahoo.comAxonics to Report Fourth Quarter 2022 Financial Results on March 1March 30, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. January 31, 2023 | finance.yahoo.comAxonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemJanuary 12, 2023 | finance.yahoo.comWhen Will Axonics, Inc. (NASDAQ:AXNX) Breakeven?January 12, 2023 | finance.yahoo.comAxonics (AXNX) Soars 10.6%: Is Further Upside Left in the Stock?January 11, 2023 | finance.yahoo.comAxonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue GuidanceDecember 22, 2022 | finance.yahoo.comThe 6.9% return this week takes Axonics' (NASDAQ:AXNX) shareholders three-year gains to 136%December 21, 2022 | finance.yahoo.comAxonics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 13, 2022 | finance.yahoo.comShould You Invest in Axonics (AXNX)?December 13, 2022 | finance.yahoo.comShould You Invest in Axonics (AXNX)?December 13, 2022 | finance.yahoo.comAxonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation SystemNovember 18, 2022 | finance.yahoo.comAxonics® to Participate in the Piper Sandler Healthcare ConferenceNovember 16, 2022 | finance.yahoo.comAxonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North AmericaNovember 8, 2022 | finance.yahoo.comAre Investors Undervaluing Axonics, Inc. (NASDAQ:AXNX) By 36%?November 1, 2022 | finance.yahoo.comWhy Axonics (AXNX) Surged in the Third Quarter?October 24, 2022 | finance.yahoo.comAxonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?October 14, 2022 | nasdaq.com3 Medical Info System Stocks to Gain on Rising Demand for Digital Health - NasdaqOctober 10, 2022 | seekingalpha.comHot Stocks: Macau stocks drop on COVID worries; EDU, TAL fall; AXNX downgrade; IMTX rises - Seeking AlphaOctober 10, 2022 | benzinga.comAxonics Risk/Reward Ratio Is Less Favorable, Analyst Says While Downgrading Stock - Axonics (NASDAQ:AXNX) - BenzingaOctober 10, 2022 | benzinga.comAxonics shares are trading lower after analysts at Needham downgraded their rating of the stock from Buy to Hold. - Axonics (NASDAQ:AXNX) - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXNX Company Calendar Last Earnings3/01/2023Today3/30/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXNX CUSIPN/A CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees517Year FoundedN/APrice Target and Rating Average Stock Price Forecast$79.00 High Stock Price Forecast$90.00 Low Stock Price Forecast$69.00 Forecasted Upside/Downside+41.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,700,000.00 Net Margins-21.81% Pretax Margin-22.77% Return on Equity-11.82% Return on Assets-10.24% Debt Debt-to-Equity RatioN/A Current Ratio7.13 Quick Ratio6.27 Sales & Book Value Annual Sales$273.70 million Price / Sales10.22 Cash FlowN/A Price / Cash FlowN/A Book Value$11.51 per share Price / Book4.87Miscellaneous Outstanding Shares49,964,000Free Float48,810,000Market Cap$2.80 billion OptionableNot Optionable Beta0.41 Key ExecutivesRaymond Wayne CohenChief Executive Officer & DirectorDanny L. DearenPresident & Chief Financial OfficerRinda K. SamaChief Operating OfficerGuang Qiang JiangChief Technology OfficerKaren NoblettChief Medical OfficerKey CompetitorsTandem Diabetes CareNASDAQ:TNDMGlaukosNYSE:GKOSInari MedicalNASDAQ:NARINuVasiveNASDAQ:NUVAiRhythm TechnologiesNASDAQ:IRTCView All CompetitorsInsiders & InstitutionsDiametric Capital LPBought 12,291 shares on 3/29/2023Ownership: 0.072%Victory Capital Management Inc.Sold 200,874 shares on 3/10/2023Ownership: 0.719%Rockefeller Capital Management L.P.Sold 563 shares on 3/6/2023Ownership: 0.005%Voya Investment Management LLCSold 63,560 shares on 2/28/2023Ownership: 0.595%NatixisSold 47,403 shares on 2/24/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions AXNX Stock - Frequently Asked Questions Should I buy or sell Axonics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXNX shares. View AXNX analyst ratings or view top-rated stocks. What is Axonics' stock price forecast for 2023? 8 Wall Street analysts have issued 1 year target prices for Axonics' stock. Their AXNX share price forecasts range from $69.00 to $90.00. On average, they anticipate the company's stock price to reach $79.00 in the next year. This suggests a possible upside of 41.0% from the stock's current price. View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts. How have AXNX shares performed in 2023? Axonics' stock was trading at $62.53 on January 1st, 2023. Since then, AXNX shares have decreased by 10.4% and is now trading at $56.01. View the best growth stocks for 2023 here. When is Axonics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our AXNX earnings forecast. How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) issued its quarterly earnings results on Wednesday, March, 1st. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.24. The firm had revenue of $85.90 million for the quarter, compared to the consensus estimate of $84.14 million. Axonics had a negative trailing twelve-month return on equity of 11.82% and a negative net margin of 21.81%. Axonics's revenue for the quarter was up 61.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.34) earnings per share. What ETFs hold Axonics' stock? ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Neuberger Berman Disrupters ETF (NBDS), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), Nuveen Small Cap Select ETF (NSCS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust US Equity Opportunities ETF (FPX) and Principal Healthcare Innovators ETF (BTEC). What guidance has Axonics issued on next quarter's earnings? Axonics issued an update on its FY 2023 earnings guidance on Thursday, March, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $342.00 million-$342.00 million, compared to the consensus revenue estimate of $336.36 million. What is Raymond W. Cohen's approval rating as Axonics' CEO? 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT). When did Axonics IPO? (AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. What is Axonics' stock symbol? Axonics trades on the NASDAQ under the ticker symbol "AXNX." Who are Axonics' major shareholders? Axonics' stock is owned by a number of institutional and retail investors. Top institutional investors include Bamco Inc. NY (3.58%), Lord Abbett & CO. LLC (3.37%), Norges Bank (2.47%), Credit Suisse AG (1.94%), Fred Alger Management LLC (1.86%) and Geode Capital Management LLC (1.85%). Insiders that own company stock include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara. View institutional ownership trends. How do I buy shares of Axonics? Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axonics' stock price today? One share of AXNX stock can currently be purchased for approximately $56.01. How much money does Axonics make? Axonics (NASDAQ:AXNX) has a market capitalization of $2.80 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. How many employees does Axonics have? The company employs 517 workers across the globe. How can I contact Axonics? Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321. This page (NASDAQ:AXNX) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.